A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy

A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy

Background: The incidence and mortality of lung cancer are high, and treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is the preferred first-line treatment for patients suffering from non-small cell lung cancer (NSCLC) with EGFR mutations. However, EGFR-TKI resist...

Full description

Bibliographic Details
Main Authors: Jue Zhang, Zhipeng Qu, Xi Xiao, David L. Adelson, Funeng Wang, Aisheng Wei, Yuka Harata-Lee, Jian Cui, Dongying He, Le Xie, Lingling Sun, Jing Li, Zijing Huang, Thazin Aung, Hong Yao, Lizhu Lin
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Heliyon
Subjects:
Non-small cell lung cancer
Yifei-Sanjie pill
Drug resistance
Autophagy
PI3K/Akt/mTOR pathway
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024171356

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024171356

Similar Items